Krystal Biotech reports Q1 EPS $1.83, consensus $1.42

Reports Q1 revenue $116.36M, consensus $112.13M. “Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish Krishnan, chairman and CEO of Krystal Biotech (KRYS). “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”